{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.3","upperLimit":"84.6","value":"75.9"},{"groupId":"OG001","lowerLimit":"68.6","upperLimit":"86.9","value":"78.8"},{"groupId":"OG002","lowerLimit":"58.2","upperLimit":"84.7","value":"72.9"},{"groupId":"OG003","lowerLimit":"69.1","upperLimit":"90.9","value":"81.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"55"}],"units":"Participants"}],"description":"Percentages of patients with responses after radiation therapy (induction therapy) are reported with 95% confidence intervals. Complete and partial responses were considered responses.","dispersionType":"95% Confidence Interval","groups":[{"description":"Medulloblastoma patients who received regimen A (no carboplatin / no isotretinoin)","id":"OG000","title":"Regimen A (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen B (carboplatin / no isotretinoin)","id":"OG001","title":"Regimen B (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen C (no carboplatin / isotretinoin)","id":"OG002","title":"Regimen C (Medulloblastoma Patients)"},{"description":"Medulloblastoma patients who received regimen D (carboplatin / isotretinoin)","id":"OG003","title":"Regimen D (Medulloblastoma Patients)"}],"paramType":"NUMBER","populationDescription":"83 of 87 eligible Arm A medulloblastoma patients were evaluated for response after induction, as were 85/89, 48/53, and 55/56 arm B, C, and D patients, respectively.","reportingStatus":"POSTED","timeFrame":"12 weeks after treatment initiation","title":"Tumor Response to Radiation Therapy for Patients With Medulloblastoma","type":"SECONDARY","unitOfMeasure":"percentage of patients"}